Loading clinical trials...
Loading clinical trials...
A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Conditions
Interventions
TY-2136b
TY-2136b
Locations
2
United States
Rhode Island Hospital, Brown University
Providence, Rhode Island, United States
Oncology Consultants
Houston, Texas, United States
Start Date
April 20, 2023
Primary Completion Date
January 1, 2025
Completion Date
October 1, 2025
Last Updated
April 24, 2023
NCT05919264
NCT07403721
NCT03093116
NCT07213817
NCT06248411
NCT04977453
Lead Sponsor
TYK Medicines, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions